Arbutus Biopharma
ABUS
ABUS
59 hedge funds and large institutions have $67.4M invested in Arbutus Biopharma in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 18 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
59
Holders Change
+4
Holders Change %
+7.27%
% of All Funds
1.17%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
%
% of All Funds
0.02%
New
15
Increased
10
Reduced
18
Closed
11
Calls
$501K
Puts
–
Net Calls
+$501K
Net Calls Change
+$509K
Top Buyers
1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$10.3M |
2 |
Jennison Associates
New York
|
+$6.06M |
3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.27M |
4 |
CAC
Cowen and Company
New York
|
+$2.58M |
5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$797K |
Top Sellers
1 |
Primecap Management
Pasadena,
California
|
-$9.57M |
2 |
BlackRock
New York
|
-$1.59M |
3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$806K |
4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$763K |
5 |
Renaissance Technologies
New York
|
-$257K |